Kendall & Taylor Atkinson Foundation

What it reported doing in 2023

**allocations were made to the fanconi anemia research fund to support medical, scientific and treatment research of fanconi anemia and its related cancers.*$72,513 was allocated to fund research entitled "transforming treatment of inherited bone marrow failure in fanconi anemia by precise in vivo genome editing."people with fa, who have bone marrow failure, are currently treated with allogeneic hematopoietic stem cell transplants. However, these procedures remain somewhat limited due to high cost, lack of appropriate donors in some regions, and heightened risk of long-term health effects such as an increased risk of cancer. In vivo gene therapies offer promise and great potential for a sage easily accessible, and cost-effective therapeutic option to treat fa-related bone marrow failure that can be used worldwide. This consortium will test gene editing technologies for all major fa mutations using laboratory-based techniques over the next two years. The goal is to rapidly develop a translational protocol that will eventually be tested in clinical trials.**allocations were made to the university of Colorado foundation. *an allocation of $20,000 was made to the university of Colorado foundation for the kenneth r atkinson md endowed memorial scholarship.distribution of funds was made to an endowed scholarship to be awarded annually to a student enrolled in the school of medicine at the university of Colorado anschutz medical campus. Scholarship is need based with preference given to 4th year medical students who plan on going into primary care medicine. Preference will also be given to students intending to practice primary care in the state of Colorado.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 89.4%; rating input score 89
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 80th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 3 of 7 controls in place; rating input score 43
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Fail
  • Document-retention policy: Fail
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -359.1%; rating input score 10; 10th percentile among comparable filings
• Total-asset coverage ratio: 0; rating input score 3; 3rd percentile among comparable filings
• Liabilities to assets ratio: Limited
• Officer compensation ratio: 0%; rating input score 60; 60th percentile among comparable filings

Growth

• Program expense growth: -3.6% per year; rating input score 0; 42nd percentile among comparable filings
• Revenue growth: -2.6% per year; rating input score 0; 52nd percentile among comparable filings
• Asset growth: 8.7% per year; rating input score 100; 78th percentile among comparable filings